Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response claim matches the provided FDA label stewardship language requiring use only for infections proven or strongly suspected to be caused by susceptible/appropriate bacteria, including the rationale regarding maintaining effectiveness and reducing drug-resistant bacteria development.
Category Scores
Accurate Statements
Doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria (and this is intended to reduce development of drug-resistant bacteria and maintain effectiveness).
Sections 1 and 1.10: “should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria/bacteria” plus rationale to “reduce the development of drug-resistant bacteria and maintain the effectiveness.”
Prescribing doxycycline in the absence of proven or strongly suspected bacterial infection is unlikely to provide benefit and increases risk of development of drug-resistant bacteria.
PRECAUTIONS (General) and related boxed warning/prevention text excerpt: “Prescribing ... in the absence of proven or strongly suspected bacterial infection ... is unlikely to provide benefit ... and increases the risk of the development of drug-resistant bacteria.”
Unsupported Statements
Contradictions
Important Omissions
The AI response did not explicitly mention the “When culture and susceptibility information are available, they should be considered…” or “In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.”
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim aligns with on-label antimicrobial stewardship language and does not introduce contraindicted or unsafe instructions beyond the label-supported restriction of use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: the AI response did not include label text about considering culture/susceptibility data and local epidemiology when selecting or modifying therapy.
Suggested Improvement
Add the label-supported statements about using culture/susceptibility information when available and using local epidemiology/susceptibility patterns for empiric selection when such data are absent.